9月10日 - ** PMV制药公司PMVP.O股价盘前上涨30.6%至2.08美元
** 实验性疗法 rezatapopt 在中期研究中显示，TP53 基因突变的晚期实体瘤患者的肿瘤缩小了 - co
** 中期数据显示，晚期实体瘤患者的总体反应率为 33%，中位反应持续时间为 6.2 个月
** 该疗法在肺癌、乳腺癌和结直肠癌等八种不同类型的肿瘤中显示出反应
** PMVP 计划在 2027 年第一季度申请治疗难治性卵巢癌的新药
** 截至上次收盘，股价累计上涨 6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.